miR-9 functions as a tumor inhibitor of cell proliferation in epithelial ovarian cancer through targeting the SDF-1/CXCR4 pathway

He,Lin; Zhang,Li; Wang,Mengfei; Wang,Wenrong

doi:10.3892/etm.2017.4118

miR-9 functions as a tumor inhibitor of cell proliferation in epithelial ovarian cancer through targeting the SDF-1/CXCR4 pathway

Authors:
- Lin He
- Li Zhang
- Mengfei Wang
- Wenrong Wang
View Affiliations

Affiliations: Department of Gynecology, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, Jiangsu 214002, P.R. China
Published online on: February 10, 2017 https://doi.org/10.3892/etm.2017.4118
Pages: 1203-1208
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to investigate the potential role of miR-9 in the inhibition of ovarian cancer progression through the stromal cell-derived factor-1 (SDF‑1)/ C‑X‑C chemokine receptor type 4 (CXCR4) pathway and to provide a theoretical basis for the diagnosis and treatment of ovarian cancer. Human ovarian cancer OVCAR‑3 cells were transfected with miR-9 short hairpin RNA (shRNA). The effect of miR‑9 on the mRNA expression levels of CXCR4 were analyzed using reverse transcription‑quantitative polymerase chain reaction. The effects of miR‑9 on OVCAR‑3 cell proliferation, invasion and apoptotic ability were detected using a 3‑(4,5‑dimethyl‑2‑thiazolyl)‑2,5‑diphenyl tetrazolium bromide assay, Matrigel method, and Annexin V‑fluorescein isothiocyanate flow cytometry, respectively. In addition, expression levels of SDF‑1/CXCR4 pathway associated proteins were determined by western blot analysis. mRNA expression levels of CXCR4 in OVCAR‑3 cells transfected with miR‑9 shRNA was significantly downregulated compared with the blank and control groups (P<0.05). Furthermore, compared with the two control groups, the current results revealed that miR‑9 inhibited cell proliferation, suppressed invasive ability and induced cell apoptosis in OVCAR‑3 cells (P<0.05). Finally, it was observed that miR‑9 functioned as a tumor inhibitor through the SDF‑1/CXCR4 pathway by suppressing the expression levels of extracellular signal‑regulated kinase 1 (ERK1), ERK2 and matrix metalloproteinase‑9 proteins. The present study suggested that miR‑9 may function as a promising tumor inhibitor for ovarian cancer through targeting the SDF-1/CXCR4 pathway.

View Figures

View References

1	Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP and Mori S: Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 34:1899–1907. 2015. View Article : Google Scholar : PubMed/NCBI
2	Nik NN, Vang R, Shih IeM and Kurman RJ: Origin and pathogenesis of pelvic (ovarian, tubal and primary peritoneal) serous carcinoma. Ann Rev Pathol. 9:27–45. 2014. View Article : Google Scholar
3	Marcus CS, Maxwell GL, Darcy KM, Hamilton CA and McGuire WP: Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 5:25–30. 2014. View Article : Google Scholar : PubMed/NCBI
4	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
5	Tone AA, McConechy MK, Yang W, Ding J, Yip S, Kong E, Wong KK, Gershenson DM, Mackay H, Shah S, et al: Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer. 14:9822014. View Article : Google Scholar : PubMed/NCBI
6	Dillman RO, DePriest C, Ellis R and de Leon C: 5-year survival for patients with metastatic melanoma who had no evidence of disease at time of treatment with patient specific tumor stem cell vaccines. Cancer Res. 74 Suppl 19:1972014. View Article : Google Scholar
7	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
8	Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
9	Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, Sonego M, Cirombella R, Onesti EC, Pellegrini P, et al: A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci USA. 110:9845–9850. 2013. View Article : Google Scholar : PubMed/NCBI
10	Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA and Skotheim RI: MiR-9, −31, and −182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia. 14:868–879. 2012. View Article : Google Scholar : PubMed/NCBI
11	Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, et al: Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer. 7:352008. View Article : Google Scholar : PubMed/NCBI
12	Tang H, Yao L, Tao X, Yu Y, Chen M, Zhang R and Xu C: miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting TLN1. Int J Mol Med. 32:381–388. 2013.PubMed/NCBI
13	Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931. 2010. View Article : Google Scholar : PubMed/NCBI
14	Yu Y, Shi X, Shu Z, Xie T, Huang K, Wei L, Song H, Zhang W and Xue X: Stromal cell-derived factor-1 (SDF-1)/CXCR4 axis enhances cellular invasion in ovarian carcinoma cells via integrin β1 and β3 expressions. Oncol Res. 21:217–225. 2013. View Article : Google Scholar : PubMed/NCBI
15	Kinouchi M, Uchida D, Kuribayashi N, Tamatani T, Nagai H and Miyamoto Y: Isolation of a novel metastasis-related microRNA, miR-518c-5p, induced by the stromal cell-derived factor (SDF)-1/CXCR4 system in oral cancer. Cancer Res. 74 Suppl 19:14462014. View Article : Google Scholar
16	Hummon AB, Lim SR, Difilippantonio MJ and Ried T: Isolation and solubilization of proteins after TRIzol extraction of RNA and DNA from patient material following prolonged storage. Biotechniques. 42:467–470. 2007. View Article : Google Scholar : PubMed/NCBI
17	Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT and Donahoe PK: Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA. 103:11154–11159. 2006. View Article : Google Scholar : PubMed/NCBI
18	Shirali S, Aghaei M, Shabani M, Fathi M, Sohrabi M and Moeinifard M: Adenosine induces cell cycle arrest and apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian cancer cell line OVCAR-3. Tumor Biol. 34:1085–1095. 2013. View Article : Google Scholar
19	Zetter BR: Angiogenesis and tumor metastasis. Ann Rev Med. 49:407–424. 1998. View Article : Google Scholar : PubMed/NCBI
20	Steeg PS: Tumor metastasis: Mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
21	Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X and Tang H: MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 276:5537–5546. 2009. View Article : Google Scholar : PubMed/NCBI
22	Tan HX, Wang Q, Chen LZ, Huang XH, Chen JS, Fu XH, Cao LQ, Chen XL, Li W and Zhang LJ: MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol. 27:654–660. 2010. View Article : Google Scholar : PubMed/NCBI
23	Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, et al: A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA. 105:13556–13561. 2008. View Article : Google Scholar : PubMed/NCBI
24	Obermajer N, Muthuswamy R, Odunsi K, Edwards RP and Kalinski P: PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71:7463–7470. 2011. View Article : Google Scholar : PubMed/NCBI
25	Hall JM and Korach KS: Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis. Mol Carcinog. 52:715–725. 2013. View Article : Google Scholar : PubMed/NCBI
26	Popple A, Durrant L, Spendlove I, Rolland P, Scott IV, Deen S and Ramage JM: The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer. Br J Cancer. 106:1306–1313. 2012. View Article : Google Scholar : PubMed/NCBI
27	Lu J, Luo H, Liu X, Peng Y, Zhang B, Wang L, Xu X, Peng X, Li G, Tian W, et al: miR-9 targets CXCR4 and functions as a potential tumor suppressor in nasopharyngeal carcinoma. Carcinogenesis. 35:554–563. 2014. View Article : Google Scholar : PubMed/NCBI
28	Yu T, Liu K, Wu Y, Fan J, Chen J, Li C, Yang Q and Wang Z: MicroRNA-9 inhibits the proliferation of oral squamous cell carcinoma cells by suppressing expression of CXCR4 via the Wnt/β-catenin signaling pathway. Oncogene. 33:5017–5027. 2014. View Article : Google Scholar : PubMed/NCBI
29	Hatano K, Yamaguchi S, Nimura K, Murakami K, Nagahara A, Fujita K, Uemura M, Nakai Y, Tsuchiya M, Nakayama M, et al: Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc. Mol Cancer Res. 11:1088–1100. 2013. View Article : Google Scholar : PubMed/NCBI
30	Yu T, Wu Y, Helman JI, Wen Y, Wang C and Li L: CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res. 9:161–172. 2011. View Article : Google Scholar : PubMed/NCBI
31	Roomi M, Monterrey J, Kalinovsky T, Rath M and Niedzwiecki A: In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors. Oncol Rep. 23:605–614. 2010.PubMed/NCBI
32	Yu Y, Li H, Xue B, Jiang X, Huang K, Ge J, Zhang H and Chen B: SDF-1/CXCR7 axis enhances ovarian cancer cell invasion by MMP-9 expression through p38 MAPK pathway. DNA Cell Biol. 33:543–549. 2014. View Article : Google Scholar : PubMed/NCBI